| Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. | |
| | |
MedLine Citation:
|
PMID: 15025679 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Cardiovascular disease is associated with platelet dysfunction in patients with diabetes. Hyperglycaemia is known as an independent risk factor for micro- and macrovascular complications, and improvement of metabolic control has shown beneficial effects on diabetic late complications. Our study attempts to clarify the effect of improved metabolic control on platelet activation markers in patients with type-2 diabetes. MATERIALS AND METHODS: Thirty patients were studied at baseline and 3 months after improvement of metabolic control and compared with an age-matched nondiabetic control group. Platelet activation markers (CD31, CD36, CD49b, CD62P and CD63) were assessed by flow cytometry analysis. RESULTS:Significantly more activated platelets were detected in patients with diabetes compared with controls. After 3 months' improvement of metabolic control, a significant decline of all platelet activation markers except CD36 was noted. Furthermore a significant correlation between CD62P, CD63 and HbA(1c) levels was observed. CONCLUSIONS: We conclude therefore that improvement of metabolic control has a beneficial effect on platelet activation. This may have an implication in the pathogenesis of vascular disease in patients with type-2 diabetes. |
| | |
Authors:
|
N Eibl; W Krugluger; G Streit; K Schrattbauer; P Hopmeier; G Schernthaner |
Related Documents
:
|
2736879 - Platelet efflux of noradrenaline in patients with type 1 diabetes mellitus. 21043929 - Enhanced spontaneous platelet aggregation and red blood cell fragility in whole blood o... 2951159 - Paradoxical platelet behaviour in diabetic ketoacidosis. 543389 - Clinical features and risk factors in stroke in young. 2916459 - Ability of whole blood aggregometer to detect platelet hyperaggregability. 14676049 - Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict c... 17415649 - Role of platelet-activating factor in acid-induced esophageal mucosal injury. 10224309 - Methylene blue inhibits hippocampal nitric oxide synthase activity in vivo. 3488779 - The role of lactoferrin released by phagocytosing neutrophils in the regulation of colo... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: European journal of clinical investigation Volume: 34 ISSN: 0014-2972 ISO Abbreviation: Eur. J. Clin. Invest. Publication Date: 2004 Mar |
Date Detail:
|
Created Date: 2004-03-17 Completed Date: 2004-05-24 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0245331 Medline TA: Eur J Clin Invest Country: England |
Other Details:
|
Languages: eng Pagination: 205-9 Citation Subset: IM |
Affiliation:
|
Rudolfstiftung Hospital, Vienna, Austria. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antigens, CD / blood Biological Markers / blood Blood Glucose / metabolism Diabetes Mellitus, Type 2 / blood*, drug therapy Female Hemoglobin A, Glycosylated / metabolism Humans Hypoglycemic Agents / therapeutic use Male Middle Aged Platelet Activation* / drug effects Prospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, CD; 0/Biological Markers; 0/Blood Glucose; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Correlates of total homocysteine plasma concentration in type 2 diabetes.
Next Document: Use of an artificial neural network to predict Graves' disease outcome within 2 years of drug withdr...